5053 results about "Viral infection" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

To provide antibodies that bind to lymphocyte activation gene 3 (LAG3) protein, which is a T cell co-inhibitor, and methods of use.SOLUTION: In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing means of treating a disease or disorder such as cancer or viral infection. The antibodies of the present invention are useful, inter alia, for targeting immune cells expressing LAG3 and for modulating LAG3 activity.SELECTED DRAWING: None

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

Provided are methods and compounds for treating (or for use in manufacturing a pharmaceutical dosage form to treat) viral infections by administering avermectin-based bioavailable highly permeable compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of SARS-CoV-2, dengue, chikungunya, yellow fever, Zika and other viral infections.

The invention discloses a virus infection positioning detection method and system based on diffractive optics. The method comprises the following steps: acquiring diffraction fingerprints corresponding to all to-be-detected cells in an imaging area by utilizing a diffraction imaging principle; respectively extracting texture features of each diffraction fingerprint in the imaging area by using a gray level co-occurrence matrix method; the extracted texture features are compared with standard texture features pre-stored in a relation model of cell morphological change and diffraction fingerprints, so that the'cell state 'of each cell to be detected in the imaging area can be obtained, and the virus infection state of each cell in the imaging area can be positioned and identified. The efficient light diffraction spectrum system is used for virus infection detection, and the requirement for professionals and expensive and complex professional field detection equipment is eliminated. The continuous and high-throughput evaluation on the cell condition after virus infection is met, and a foundation is laid for popularization and application of a virus infection instant detection platform.

The invention relates to a monoclonal antibody for detecting human metapneumovirus, a detection reagent and application of the monoclonal antibody and the detection reagent. The monoclonal antibody or the antigen binding fragment thereof can be specifically bound with the human metapneumovirus N protein with higher affinity, has broad-spectrum effectiveness on various genotypes, and has no cross reactivity with other respiratory viruses, so that the monoclonal antibody or the antigen binding fragment thereof has huge potential application value in clinical detection of human metapneumovirus infection.

The invention provides a Chinese herbal medicine preparation for preventing and controlling African swine fever and a preparation method thereof. The Chinese herbal medicine preparation for preventing and controlling African swine fever provided by the invention comprises the following components in parts by weight: 4 parts of honeysuckle, 4 parts of fructus forsythiae, 5 parts of radix isatidis, 2 parts of astragalus membranaceus, 1 part of rhodiola rosea, 3 parts of anise, 0.5 part of roasted ephedra, 1 part of fried almond, 2 parts of gypsum, 2 parts of houttuynia cordata, 0.5 part of rheum officinale, 2 parts of rhizoma dryopteris crassirhizomae, 1 part of pogostemon cablin, 0.5 part of mint, 1 part of lalang grass rhizome, 1 part of dendrobe, 0.5 part of coptis chinensis and 0.5 part of liquorice. The Chinese herbal medicine preparation for preventing and controlling the African swine fever, provided by the invention, contains chlorogenic acid, luteoloside, calycosin-7-glucoside, forsythin, (R, S)-epigoitrin and aspimaric acid. And aspidin. And mongolic acid and the like. The composition has the functions of resisting viruses, resisting bacteria, improving immunity and the like. According to the Chinese herbal medicine preparation for preventing and controlling the African swine fever and the preparation method, provided by the invention, the African swine fever virus infection can be resisted, and the effect of promoting the rehabilitation of African swine fever virus recessive infected pigs is achieved.

The invention relates to a detection kit for epithelial-mesenchymal transition in EB virus infected thymoma and application, the detection kit comprises a quantum dot labeled antibody E-Cadherin and a quantum dot labeled antibody Vimentin, a quantum dot is coupled with a specific antibody, a thymoma paraffin section sample is dyed through the quantum dot and the specific antibody conjugate, and the EB virus infected thymoma is obtained. The conjugate can be specifically connected with an EMT related antigen expressed in the slice, so that the quantum dots can be used for qualitative or quantitative detection of the EMT-generated thymoma cells. The quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of epithelial cells and mesenchymal tissues in the thymoma microenvironment is achieved, number detection and position detection can be achieved, and EMT condition evaluation is facilitated.

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and relates to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises a VH CDR1, a VH CDR2 and a VH CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3, and a VL CDR1, a VL CDR2 and a VL CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 4-6. A large number of experimental studies show that the monoclonal antibody can specifically recognize and target extracellular regions of E proteins of the Japanese encephalitis virus and the Zika virus, can block combination of the E proteins and cell surface receptors, and shows efficient virus neutralizing capacity. Therefore, the antibody provided by the invention is particularly suitable for being used for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.

The invention discloses an hMPV virus fusion protein F variant, an mRNA vaccine and application of the hMPV virus fusion protein F variant and the mRNA vaccine. The hMPV fusion protein F variant has amino acid residue difference on one or more sites relative to an hMPV fusion protein F with the login number of AGJ74096.1 in a GeneBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The mRNA vaccine designed based on the hMPV fusion protein F variant can induce a strong specific antibody reaction, the durability of the antibody in vivo is strong, the induced antibody can well neutralize an hMPV strain, the amplification of the hMPV in the lung is controlled, and the immune response of the hMPV in the lung is inhibited. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for preventing hMPV virus infection related diseases and developing multi-combined vaccines.

The invention relates to the technical field of biological medicines, in particular to a polypeptide for broad-spectrum inhibition of influenza viruses and application of the polypeptide in prevention and / or treatment of influenza virus infection. The polypeptide for broad-spectrum inhibition of influenza virus comprises the following selections: (1) an amino acid sequence as shown in SEQ ID NO: 1; (2) an amino acid sequence having at least 50% homology with the amino acid sequence shown in (1); (3) amino acid sequences obtained by replacing and / or deleting and / or increasing at least one amino acid residue at any position in the amino acid sequences shown in (1) and (2); and (4) modifying the amino acid sequences shown in (1), (2) and (3) to obtain amino acid sequences. The invention comprises a peptide sequence, a derivative, a peptide composition and independent or combined application in prevention or treatment of anti-influenza viruses, such as combined medication of the polypeptide or the derivative of the polypeptide and other anti-influenza drugs.

The invention discloses a separation method of a bovine ephemeral fever virus, the obtained bovine ephemeral fever virus and application of the bovine ephemeral fever virus. Belongs to the technical field of bovine ephemeral fever virus separation. The invention aims to provide an efficient and rapid method for separating the bovine ephemeral fever virus. The invention provides a method for separating bovine ephemeral fever virus, which comprises the following steps: inoculating a bovine anticoagulant sample to KC cells for culture, harvesting virus, inoculating to grow into monolayer BHK-21 cells, and carrying out passage to obtain passage cells with cytopathy of the first generation; the virus strain can also be used for screening, preparing and detecting a bovine ephemeral fever virus antibody and preparing a bovine ephemeral fever virus infected animal model.

Disclosed are compounds of formula (I): # imgabs0 # or a salt thereof, wherein: X, Y, Z, R1, R2, R3 and n are as defined herein. Also disclosed are methods of inhibiting the activity of one or both of diacylglycerol kinase alpha (DGK alpha) and diacylglycerol kinase zeta (DGK zeta) using such compounds, as well as pharmaceutical compositions comprising such compounds. These compounds are useful for the treatment of viral infections and proliferative diseases such as cancer.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The invention relates to the technical field of biological detection, in particular to an MxA, CRP and SAA combined detection card and a preparation method and application thereof, and the preparation method comprises the following steps: 1) preparing silicon-coated high-performance time-resolved fluorescent microspheres; (2) marking of an MxA antibody; (3) marking a CRP antibody; (4) marking an SAA antibody; (5) preparing a conjugate pad; (6) preparing a nitrocellulose membrane; and (7) assembling the reagent strip. The silicon-coated high-performance time-resolved fluorescent microspheres with the particle size range of 190-352 nm are prepared, the dye embedding rate is high, the sensitivity is high, the monodispersity is good, the stability is good, the hydrophilicity is high, agglomeration is not prone to occurring, and the dye embedding rate is increased. The MxA, CRP and SAA combined detection card prepared from the silicon-coated high-performance time-resolved fluorescent microspheres can improve the accuracy of identifying bacterial infection and virus infection, and is beneficial to early diagnosis and treatment of acute respiratory infectious diseases.

The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.

The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-primase. The present disclosure further relates to the use of the compounds for the preparation a medicament for the treatment of diseases and / or condition through inhibiting viral helicase-primase. The present disclosure also relates to use of those compounds in the treatment of viral infections. The present disclosure further relates to intermediates for its preparation and to pharmaceutical compositions containing those compounds.

The invention discloses a novel application of an RNF6 gene, namely, an application of screening a medicine for preventing and / or treating Zika virus infection, aiming at inhibiting expression of the RNF6 gene or knocking out the RNF6 gene. A series of functional experiments prove that the RNF6 gene promotes the replication of the Zika virus, and the purpose of reducing the replication of the Zika virus can be achieved by using an expression inhibitor of the RNF6 gene or knocking out the RNF6 gene; experimental results show that the RNF6 gene can be used as a potential target for preventing and / or treating Zika virus infection, and a new direction is provided for development of drugs for preventing and / or treating Zika virus infection targeting the RNF6 gene in the future.

A method of treating or inhibiting a viral infection in a human subject, such as a SARS-CoV-2 infection, involves inhibiting in vivo the expression or activity of one or a combination of the subject's genes required for viral infection. Single genes or subsets of genes for inhibition of activity or expression are selected from certain identified genes. Methods of administration of certain known small molecules or other therapeutics which mimic loss of function of the identified genes are provided. Similar methods for conducting screens of host genes required for viral infection are shown.

The present disclosure provides methods of treating or preventing human immunodeficiency virus (HIV) infection in a patient, comprising orally administering to the patient a therapeutically effective amount of an HIV capsid inhibitor of formula la (e.g. lenacapavir), or a pharmaceutically acceptable salt thereof, according to a specific dosage regimen.

The invention discloses an African swine fever virus p30 protein antibody and application thereof. When the African swine fever virus p30 protein antibody is used for a competitive ELISA method, a serum sample with the p30 antibody after African swine fever virus infection can be rapidly and accurately detected, the detection time is shortened, the detection steps are simplified, the African swine fever virus p30 protein antibody has the characteristics of rapidness and high-throughput detection, and a reliable immunological technology is provided for rapidly and efficiently detecting African swine fever virus infection.

The invention provides a temperature-corrected analyte detection method, and relates to the following steps: after a series of analyte calibrators with different concentrations are added into an immunoassay test strip, measuring a signal value generated after the analyte calibrator with each concentration is captured on a detection pad of the immunoassay test strip at each segmented temperature point by using an optical analyzer; drawing a corresponding equation by taking the T / C value at each segmented temperature point as an X axis and the concentration of the analyte calibrator as a Y axis; and then, according to the selected n segmented temperature points, carrying out temperature segmentation, and in different temperature segments, carrying out calculation by adopting different formulas. The analyte detection method subjected to temperature correction can be used for more accurately detecting myocardial markers, upper respiratory virus infection, metabolic hormones, digestive tract series markers, allergens and the like on the basis of a time-resolved fluorescence immunoassay test.

The invention discloses paenibacillus kribbensis exopolysaccharide and application thereof in prevention and control of iridovirus diseases of micropterus salmoides. The invention provides a paenibacillus kribbensis exopolysaccharide. The paenibacillus kribbensis exopolysaccharide is prepared from a fermentation product of a paenibacillus kribbensis space mutation delta PS04-17 strain. As a fish feed additive, the paenibacillus kribbensis exopolysaccharide has better in-vivo safety, has a promoting effect on the growth of the largemouth bass, and can promote the growth and weight gain of the largemouth bass and reduce the feed coefficient of the largemouth bass. Meanwhile, as a drug for resisting LMBV virus infection, the compound can inhibit expression of viruses in target tissues, alleviate virus-induced fish body target tissue structure damage and reduce the death rate caused by virus infection. Besides, the paenibacillus kribbensis exopolysaccharide serving as a disease-resistant immunopotentiator can maintain intestinal health of the micropterus salmoides, is simple to prepare, low in cost and easy to obtain in quantity, and provides more products and methods for prevention and control of the iridovirus disease of the micropterus salmoides.

The invention provides a compound shown in a formula (I) or a tautomer, a stereoisomer, an isotope derivative or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has a good inhibition effect on RSV (Respiratory Syndrome Virus). # imgabs0 #

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.